December 31, 2013 | Hadasit Bio-Holdings, the commercialization branch of Hadassah Medical Center, has received NIS 25 million (approx. $7.2 million) from the Office of the Chief Scientist. The funds will be directed towards three of Hadasit’s portfolio companies: Cell Cure, KAHR Medical and Enlivex Therapeutics.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Facebook comments